CN102875544B - 琥珀酸索非那新的制备工艺 - Google Patents
琥珀酸索非那新的制备工艺 Download PDFInfo
- Publication number
- CN102875544B CN102875544B CN201210348560.7A CN201210348560A CN102875544B CN 102875544 B CN102875544 B CN 102875544B CN 201210348560 A CN201210348560 A CN 201210348560A CN 102875544 B CN102875544 B CN 102875544B
- Authority
- CN
- China
- Prior art keywords
- solifenacin
- alkali
- reaction
- preparation technology
- tetrahydroisoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 238000005516 engineering process Methods 0.000 title claims abstract description 23
- FBOUYBDGKBSUES-KEKNWZKVSA-N 1-azabicyclo[2.2.2]octan-3-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(OC2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-KEKNWZKVSA-N 0.000 title abstract description 5
- 229960001368 solifenacin succinate Drugs 0.000 title abstract description 5
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims abstract description 56
- 238000006243 chemical reaction Methods 0.000 claims abstract description 35
- 229960003855 solifenacin Drugs 0.000 claims abstract description 31
- 239000003513 alkali Substances 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 67
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 42
- 229960000948 quinine Drugs 0.000 claims description 33
- LUMNWCHHXDUKFI-UHFFFAOYSA-N 5-bicyclo[2.2.1]hept-2-enylmethanol Chemical compound C1C2C(CO)CC1C=C2 LUMNWCHHXDUKFI-UHFFFAOYSA-N 0.000 claims description 31
- NGOPMUKKPNKRQR-CKUXDGONSA-N NC(N)=O.C1C2=CC=CC=C2[C@H](C2=CC=CC=C2)NC1.Cl Chemical compound NC(N)=O.C1C2=CC=CC=C2[C@H](C2=CC=CC=C2)NC1.Cl NGOPMUKKPNKRQR-CKUXDGONSA-N 0.000 claims description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 239000005457 ice water Substances 0.000 claims description 12
- PRTRSEDVLBBFJZ-HNNXBMFYSA-N (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1([C@H]2C3=CC=CC=C3CCN2)=CC=CC=C1 PRTRSEDVLBBFJZ-HNNXBMFYSA-N 0.000 claims description 11
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 8
- 239000007810 chemical reaction solvent Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 229960004756 ethanol Drugs 0.000 claims description 8
- 239000010410 layer Substances 0.000 claims description 8
- 239000012312 sodium hydride Substances 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 7
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 claims description 6
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- -1 sodium alkoxide Chemical class 0.000 claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012044 organic layer Substances 0.000 claims description 4
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 4
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- 238000009833 condensation Methods 0.000 abstract description 13
- 230000005494 condensation Effects 0.000 abstract description 13
- 230000009466 transformation Effects 0.000 abstract description 8
- 230000000269 nucleophilic effect Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 2
- 239000002184 metal Substances 0.000 abstract description 2
- AJFJHHJTKIFNBK-RSAXXLAASA-N carbamoyl chloride (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C(N)(=O)Cl.C1(=CC=CC=C1)[C@@H]1NCCC2=CC=CC=C12 AJFJHHJTKIFNBK-RSAXXLAASA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000005809 transesterification reaction Methods 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000017925 CHRM3 Human genes 0.000 description 1
- 101150060249 CHRM3 gene Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210348560.7A CN102875544B (zh) | 2012-09-19 | 2012-09-19 | 琥珀酸索非那新的制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210348560.7A CN102875544B (zh) | 2012-09-19 | 2012-09-19 | 琥珀酸索非那新的制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102875544A CN102875544A (zh) | 2013-01-16 |
CN102875544B true CN102875544B (zh) | 2015-05-20 |
Family
ID=47477097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210348560.7A Active CN102875544B (zh) | 2012-09-19 | 2012-09-19 | 琥珀酸索非那新的制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102875544B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103896938B (zh) * | 2014-04-24 | 2016-02-24 | 重庆科瑞制药(集团)有限公司 | 一种琥珀酸索利那新的制备方法 |
CN104447734A (zh) * | 2014-12-11 | 2015-03-25 | 荆楚理工学院 | 一种琥珀酸索利那新的合成方法 |
CN104592221A (zh) * | 2015-01-26 | 2015-05-06 | 中山奕安泰医药科技有限公司 | 一种合成索非那新的工艺 |
KR20190033569A (ko) | 2016-07-21 | 2019-03-29 | 가부시키가이샤 가네카 | 유기 화합물의 제조 방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009142522A1 (en) * | 2008-05-23 | 2009-11-26 | Zaklady Farmaceutyczne Polpharma Sa | Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity |
WO2011086003A1 (en) * | 2010-01-18 | 2011-07-21 | Zaklady Farmaceutyczne Polpharma Sa | Process for the preparation of solifenacin and solifenacin succinate |
-
2012
- 2012-09-19 CN CN201210348560.7A patent/CN102875544B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009142522A1 (en) * | 2008-05-23 | 2009-11-26 | Zaklady Farmaceutyczne Polpharma Sa | Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity |
WO2011086003A1 (en) * | 2010-01-18 | 2011-07-21 | Zaklady Farmaceutyczne Polpharma Sa | Process for the preparation of solifenacin and solifenacin succinate |
Also Published As
Publication number | Publication date |
---|---|
CN102875544A (zh) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103524440B (zh) | 痛风治疗药Lesinurad的制备方法及Lesinurad中间体 | |
CN104045637B (zh) | 一种阿哌沙班的制备方法 | |
EP3398952B1 (en) | Synthesis process of ruxolitinib | |
CN101792400B (zh) | 一种阿戈美拉汀的合成方法 | |
CN106279074A (zh) | 一种化合物及其制备方法和在合成布瓦西坦中的用途 | |
CN101798270B (zh) | 一种3-氨基-1-金刚烷醇的制备方法 | |
CN102875544B (zh) | 琥珀酸索非那新的制备工艺 | |
CN101219997A (zh) | 一种2-氯-5-氨基嘧啶的合成方法 | |
CN102219733A (zh) | 索拉非尼的制备方法 | |
CN102617542B (zh) | 一种奥美沙坦中间体的制备方法及纯化方法 | |
CN107141261A (zh) | 喹唑啉类化合物及其制备方法和在制备酪氨酸激酶抑制剂中的应用 | |
CN104045602A (zh) | 一种缬沙坦成四氮唑的改进方法 | |
CN103204801A (zh) | N-Boc-3-哌啶酮的合成方法 | |
CN103980336A (zh) | 一种新的氟维司群的合成方法 | |
CN101531654B (zh) | 一种卢帕他定的制备方法 | |
CN105330598A (zh) | 一种吡非尼酮的制备方法 | |
CN105646285B (zh) | 一种维兰特罗中间体及其制备方法和应用 | |
CN101654419A (zh) | 马来酸氟伏沙明的制备方法 | |
CN103664952B (zh) | 一种佐匹克隆的制备方法 | |
CN101747278A (zh) | 1-氯甲酰基-3-甲磺酰基-2-咪唑烷酮的合成方法 | |
CN1321975C (zh) | 4-[(4-氧代-3-溴)丁基]苯甲酰-l-谷氨酸二乙酯及制备和应用 | |
CN102260213B (zh) | 一种托伐普坦的制备方法 | |
CN105315169A (zh) | 一种心血管疾病治疗药物的制备方法 | |
CN102399235A (zh) | 一种2-氨基-5-嘧啶硼酸频哪醇酯的合成方法 | |
CN101985451A (zh) | 普拉格雷中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ye Ding Inventor after: Gao Jian Inventor after: Liu Lichao Inventor after: Liu Ping Inventor before: Ye Ding Inventor before: Gao Jian Inventor before: Liu Lichao |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YE DING GAO JIAN LIU LICHAO TO: YE DING GAO JIAN LIU LICHAO LIU PING |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation technology of solifenacin succinate Effective date of registration: 20191028 Granted publication date: 20150520 Pledgee: Chengdu technical transformation incubator management Co., Ltd. Pledgor: Chengdu Sino-Strong Pharmaceutical Co., Ltd. Registration number: Y2019510000042 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201223 Granted publication date: 20150520 Pledgee: Chengdu technical transformation incubator management Co.,Ltd. Pledgor: CHENGDU SINO-STRONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2019510000042 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of sofenacin succinate Effective date of registration: 20201228 Granted publication date: 20150520 Pledgee: Chengdu technical transformation incubator management Co.,Ltd. Pledgor: CHENGDU SINO-STRONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020510000119 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220106 Granted publication date: 20150520 Pledgee: Chengdu technical transformation incubator management Co.,Ltd. Pledgor: CHENGDU SINO-STRONG PHARMACEUTICAL Co.,Ltd. Registration number: Y2020510000119 |